Skip to main content

Table 2 Previous reports on cyclins D2 and D3 expression by immunohistochemistry in DLBCLs

From: De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression

Reference (reference no.) No. of patients Cut-off line (%) Positive cases (%)
Cyclin D2 Cyclin D3
Hans CP, et al., 2004[8] 152 30 13 ND
Hans CP, et al., 2005[9] 200 30 19 62
Amen F, et al., 2007[10] 80 10 25 ND
Metcalf RA, et al., 2010[3] 194 20 49 20
Present study CD5+ DLBCLs 51 20 98 35
        CD5 DLBCLs 51 20 28 47
  1. ND, not done.